Latest News

The tool can estimate recurrence risk across multiple subtypes, including those for which no guideline-recommended genomic prognostic tests currently exist.

Ennumo is approved for the same indications as its reference product, Neulasta (pegfilgrastim).

The new program gives eligible Medicare Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for weight management at a flat $50 co-pay, but early claim-routing errors show pharmacists have a critical role in getting patients across the bridge.

These recommendations for acute pulmonary embolism management are most applicable to pharmacists on the interdisciplinary team managing acute PE.

Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, discusses multimodal analgesia, acute pain pathways, opioid-tolerant patients, suzetrigine, and pharmacist-led interventions across health systems with Pharmacy Times.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

New findings show chronic kidney disease affects the same share of US adults as in 2013, although the disease is increasingly tied to diabetes and heart conditions.

Study authors suggest diabetic guidelines should consider standardized reporting of CGM metrics in studies employing CGM-based interventions.

Advances in antibiotic and microbiome-based therapies may reduce recurrence and improve outcomes in patients with recurrent Clostridioides difficile infection. 

The authors said these data support the safety of current coadministration practice.

Danish study links meningioma risk to progestogen contraceptives, including injectable depot medroxyprogesterone acetate and levonorgestrel intrauterine devices.

Cyclospora cases surge nationwide; learn symptoms, testing pitfalls, treatment, and smart food-water precautions as investigators search for the source.

In an interview with Pharmacy Times, Matt Christian, director of Supply Chain Insights at USP, discussed the factors driving long-term shortages, the growing role of geographic concentration, and what pharmacists should understand about supply chain resilience.

FDA grants accelerated approval to atacicept-vymj for IgA nephropathy proteinuria, backed by ORIGIN clinical trial results.

As cannabis evolves, pharmacists must recognize emerging risks from high-potency products, drug interactions, and use-related syndromes to improve patient safety.

Laura Gillespie, PharmD, discusses how her patient-first approach has guided her research collaboration efforts and led to measurable reductions in C difficile infection rates at her institution.

Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

This study validates the need for universal HBV therapy for hepatitis B infections among people coinfected with HIV.

The FDA expanded Casgevy’s indication to include children 2 years and older with sickle cell disease with recurrent VOCs or transfusion-dependent β-thalassemia, making it the first gene therapy approved for patients as young as 2 years with SCD.

By targeting aldosterone synthesis directly, baxdrostat offers a novel mechanism for addressing resistant hypertension.